91 results
8-K
EX-10.3
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.1
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.4
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.2
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.5
SLRX
Salarius Pharmaceuticals Inc
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
EX-10.1
tjpzajz tzvoyehn0wow
14 Jun 23
Departure of Directors or Certain Officers
6:47pm
8-K
EX-10.2
6r4w3rv
16 May 23
Salarius Pharmaceuticals Announces $6 Million Private Placement
4:33pm
8-K
EX-10.1
kwh89
16 May 23
Salarius Pharmaceuticals Announces $6 Million Private Placement
4:33pm
8-K
EX-10.2
ljxnzur
22 Apr 22
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
8:47am
8-K
EX-10.1
zcab bwf990b1zag
22 Apr 22
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering
8:47am
8-K
EX-10.1
bjbsx08dvz79phuoy4
13 Jan 22
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
4:05pm
8-K
EX-10.1
gvm92go
11 Dec 20
Entry into a Material Definitive Agreement
8:28am
8-K
EX-10.1
cahtn
19 Jun 20
Submission of Matters to a Vote of Security Holders
5:26pm
8-K
EX-10.2
zfwv1itr8i
19 Jun 20
Submission of Matters to a Vote of Security Holders
5:26pm
8-K
EX-10.01
8lkz8o2k
29 Apr 20
Departure of Directors or Certain Officers
4:31pm
8-K
EX-10.1
8hzeu8ll8mttlv
28 Oct 19
Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement
8:01am
8-K
EX-10.5
a4z0mt4ngzqb7jd2q8
16 Sep 19
Departure of Directors or Certain Officers
5:15pm
8-K
EX-10.3
l8vkhhz
16 Sep 19
Departure of Directors or Certain Officers
5:15pm